National Health Service

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Retrieved on: 
Tuesday, November 14, 2023
Diet, Exercise, CGM, Obesity, Glucose, NHS, Conference, National Health Service, Quality of life, Pharmacotherapy, Sidoti, Weight loss, Education, Cryptocurrency, Pharmaceutical industry, Tirzepatide, Nemaura Medical

Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.

Key Points: 
  • This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.
  • Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.
  • In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.
  • The incorporation of GLP-1 agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of support for individuals seeking effective and sustainable weight loss.

AI Pioneer Rainbird Technologies Names Klick Health as Its Exclusive North American Life Sciences Partner

Retrieved on: 
Monday, December 4, 2023
Data Management, Technology, Marketing, Practice Management, Advertising, Pharmaceutical, Communications, General Health, Professional Services, Artificial Intelligence, Biotechnology, Science, Software, Data Analytics, Research, Health, Whitehead, Logic, National Health Service (England), Explainable artificial intelligence, Data science, Click, Ernest Ange Duez, NHS, OpenAI, Automation, Private law, National Health Service, Paramount, Partnership, ChatGPT, Mayo Clinic Proceedings, AI, Microsoft, Digital health, News, AWS, Human, Type 2 diabetes, Fine chemical, Medical device, Rainbird

Rainbird Technologies and Klick Health today announced an exclusive, new partnership that will bring Rainbird’s proven Decision Intelligence platform to life sciences companies across North America, reinforcing both companies’ success working in highly regulated industries.

Key Points: 
  • Rainbird Technologies and Klick Health today announced an exclusive, new partnership that will bring Rainbird’s proven Decision Intelligence platform to life sciences companies across North America, reinforcing both companies’ success working in highly regulated industries.
  • As the exclusive Rainbird service partner in life sciences, Klick will pair its industry-leading knowledge, data, and tools with Rainbird's decision intelligence automation platform to eliminate organizational bottlenecks and maximize opportunities for biopharmaceutical organizations bringing life-saving therapies to market.
  • James Duez, Rainbird Co-Founder and CEO, said their cutting-edge technology gives clients a major advantage over other AI solutions where compliance with regulations is paramount.
  • “We’re thrilled to join forces with Klick Health to drive exponential value in life sciences commercialization,” said Duez.

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Retrieved on: 
Monday, December 4, 2023
Oncology, Health, Health Technology, Clinical Trials, Research, Science, Biotechnology, SCCHN, Indometacin, Neck, Safety, NYSE, Radiation, Neoadjuvant therapy, Head, Risk, Patient, Zinc, FRCR, Lymph, Cancer Research UK, Survival rate, NHS, NIHR, NHS Wales, National Health Service, MD, Death, Survival, Cyclophosphamide, Recurrence, Social work, Pharmaceutical industry, Nursing, Health care

NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.

Key Points: 
  • NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
  • This published report informs UK doctors, patients, and other interested parties that NICE has started the review of Multikine and is soliciting public comment.
  • The NICE briefing includes the following statements:
    “The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy.
  • According to Cancer Research UK , an average of 12,400 cases of head and neck cancer are diagnosed each year in the UK.

NanoVibronix Issues Letter to Shareholders

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, General Health, Medical Devices, Other Health, Health, University of Southampton, National Health Service, Durable medical equipment, Third-party administrator, Organization, Patient satisfaction, Gold, Insurance, Patient, Compensated emancipation, NHS, COVID-19, CMS, University, SAW, Partnership, Growth, Medicare, Veterans Health Administration, Pharmaceutical industry, Health insurance, Marketing

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments.

Key Points: 
  • NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the third quarter 2023 and recent business developments.
  • We recorded revenues of $458,000 for the quarter ended September 30, 2023 with a loss from operations of $670,000.
  • In the relative year-to-date period, revenues increased 22% and the loss from operations was reduced by approximately 20%.
  • CMS invited NanoVibronix to a public meeting to present our findings and to answer CMS’s questions, which was held June 1, 2023.

Healthcare Executive Angela Single Joins Novari Health

Retrieved on: 
Tuesday, November 21, 2023
Health, Integrated care system, National Health Service, Registry, EPRS, Pediatrics, Privacy, PACS, Patient, HL7, NHS, API, NHS trust, FHIR, Trust, PAS, Diabetes, Endoscopy, AI, ICBS, DICOM, Nursing, Meditech

LONDON, Nov. 21, 2023 /PRNewswire/ -- Novari Health is pleased to announce that Angela Single has joined Novari as Director, UK Business Development.

Key Points: 
  • LONDON, Nov. 21, 2023 /PRNewswire/ -- Novari Health is pleased to announce that Angela Single has joined Novari as Director, UK Business Development.
  • Angela is a seasoned executive in the field of digital health.
  • John Sinclair, Chief Executive Officer of Novari Health UK Ltd., commented "Angela's clinical, administrative, and digital health experience make her an invaluable addition to the Novari global team, and we are thrilled to welcome her as our director of UK business development.
  • From its beginnings in Canada in 2003, Novari Health has focused exclusively on helping publicly funded healthcare systems to improve access to care.

ConcertAI's TeraRecon Enhances its Eureka Clinical AI Platform with AI-Based Prostate Cancer Diagnostic Solutions from Lucida Medical

Retrieved on: 
Wednesday, November 15, 2023
Lancet, Prostate, Cardiology, PACS, Urology, Patient, PROMIS, Medtech, Algorithm, Prostate cancer, Neurology, Biomedicine, ECR, NHS, National Health Service, Radiology, Diagnosis, Cancer, Partnership, Doctor of Philosophy, MRI, AI, Quality of life, Biopsy, Medical imaging

CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS company, today announced the addition of Lucida Medical to its Eureka Clinical AI Platform ecosystem.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS company, today announced the addition of Lucida Medical to its Eureka Clinical AI Platform ecosystem.
  • Pi™ (Prostate Intelligence™), Lucida Medical's AI-machine learning software, is designed to help radiologists detect prostate cancer lesions from MRI, enabling faster and more accurate prostate cancer detection.
  • Prostate cancer diagnosis using MRI represents a major step forward compared to earlier methods but remains prone to human error.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more:

Thinkspace Brings Life-Changing Wellness Pod to North America, 10-Minute Cycle Reduces Stress & Anxiety

Retrieved on: 
Thursday, November 2, 2023
History of the National Health Service, United Kingdom, Nervous system, National Health Service, Metabolism, Quality of life, Immunity, Music, Autonomic nervous system, Anxiety, Nursing, COVID-19, Medical device

CHICAGO, Nov. 2, 2023 /PRNewswire/ -- Thinkspace brings an entirely new perspective on personal human wellness to North America with the Neuron Activation Pod. The pod stimulates the autonomic nervous system using low-frequency vibrations guiding the body into a meditative state. In this state, the body naturally heals itself. The benefits of the cycle continue throughout the day increasing recovery and aiding the user to a deeper night's sleep.

Key Points: 
  • CHICAGO, Nov. 2, 2023 /PRNewswire/ -- Thinkspace brings an entirely new perspective on personal human wellness to North America with the Neuron Activation Pod .
  • The benefits of the cycle continue throughout the day increasing recovery and aiding the user to a deeper night's sleep.
  • "The statistics on stress and anxiety in the United States stunned me," said Anjul Chandi, CEO of Thinkspace.
  • Kevin Lahtinen, LoOok Industries
    The Neuron Activation Pod can be tested in 15 locations across North America.

Mo[+] Plus: Composite Product for Hair Care by Mirae Wellcare

Retrieved on: 
Wednesday, October 25, 2023
Vitamins, Supplements, Fitness & Nutrition, Health, Other Health, Food safety, Hair loss, HACCP, National Health Service, Certification, Health Insurance Review and Assessment Service, Accreditation, Korean Ministry of Culture, Tablet, Hair, Biotin, Assessment, Patient, Alopecia areata, Dietary supplement, Food

Mirae Wellcare, a South Korean health food provider, introduces Mo[+] Plus, a hair care composite product that promotes healthy hair.

Key Points: 
  • Mirae Wellcare, a South Korean health food provider, introduces Mo[+] Plus, a hair care composite product that promotes healthy hair.
  • Biotin, in particular, is an essential nutrient for hair strengthening, organization, and production.
  • Prior to the manufacturing process, all raw materials of Mo[+] Plus are subject to metal contamination and E. coli testing.
  • In appreciation of its safe production procedure, the product acquired HACCP accreditation, a food safety management certification.

United Kingdom Compact Construction Equipment Market Assessment & Forecast Report 2023-2029: Affordable Housing Initiatives and Investment in National Healthcare Plan to Spur Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Construction & Property, Other Construction & Property, E-commerce, ONS, Ageing, Bank, BP, Housing, HIP, Construction, Government, Foodservice, National Health Service, Ship, Workforce, Wind, Statistics, Compact, Komatsu, Hydrogen, Growth, Hospital, Health, Emergency medical services, Volvo, USD, Accommodation, Renewable energy, Building material, Investment, Caterpillar, Bed, Residential area, JCB, Heavy equipment, Warehouse, Real estate, Nursing, Cassette tape, Takeuchi, Kubota

The "UK Compact Construction Equipment Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UK Compact Construction Equipment Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.
  • This growth in the logistics and e-commerce sectors is expected to have a positive impact on the demand for compact forklifts within the U.K. compact construction equipment market.
  • Caterpillar, Komatsu, Volvo CE, and JCB are among the top revenue generators in the U.K. compact construction equipment market.
  • Compact Construction Equipment Market Growth
    The government introduced an affordable housing delivery plan for 2022-2025 in Bristol City in 2021.

"I LOVE FRUIT & VEG FROM EUROPE" HIGHLIGHTS THE HEALTH BENEFITS OF AUTUMN'S NUTRITIONALLY RICH APPLES, GRAPES, ORANGES, BEETROOT AND PUMPKIN

Retrieved on: 
Tuesday, October 10, 2023
European, Health, Diet, Tryptophan, Antioxidant, National Health Service, Vegetable, Taste, Safety, Seed, WHO, NHS, Nitrate, Dietary supplement

LONDON, Oct. 10, 2023 /PRNewswire/ -- 'I Love Fruit & Veg from Europe' is championing an autumnal bounty of nutrient-packed, mood-boosting and flavour-rich produce in an October campaign spotlighting orchard fruits, root vegetables and seasonal squashes. Co-funded by the European Union and steered by five leading Italian agricultural organisations, the programme promotes the quality, environmental sustainability, safety and health benefits of produce sourced from Italy and Europe.

Key Points: 
  • Autumn's produce showcases a rich and warm colour palette that evokes the very essence of the season, from deep purples and radiant reds to vibrant oranges and earthy hues.
  • In October, the programme highlights apples, grapes, oranges, beetroot and pumpkin as they reach their peak season.
  • "Eating fruit and vegetables is among the best decisions we can make for our health and taste preferences," said Emilio Ferrara of the I Love Fruit & Veg from Europe programme.
  • "A diet rich in these foods not only boosts our well-being but also plays a crucial role in preventing many health issues.